XIDX
TSPC
Market cap794mUSD
Nov 12, Last price
2,930.00IDR
Name
Tempo Scan Pacific Tbk PT
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Tempo Scan Pacific Tbk engages in the pharmaceuticals, personal care and cosmetics, and distribution services businesses in Indonesia and internationally. The company operates through three segments: Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services. It is involved in the pharmaceutical and medical devices trading; manufacture of soaps, herbal products, powder milk, food and beverages, and plastic packaging; and manufacturing and trading of consumer products, cosmetics, and household products. The company sells its products under the Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Vidoran, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, MY BABY, MY BABY Kids, Pure Baby, S.O.S, Total Care, and ULTIMA II brands. It also engages in the construction and rental of buildings; provision of warehousing, freight forwarding, advertising and promotion, research and development, and information technology and communication network systems services; and procurement, distribution, and marketing activities. The company was formerly known as PT Scanchemie. The company was founded in 1970 and is headquartered in Jakarta, Indonesia. PT Tempo Scan Pacific Tbk is a subsidiary of PT Bogamulia Nagadi.
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||